{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:15:23Z","timestamp":1790399723339,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2242,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1093\/annonc\/mdt242","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T21:01:17Z","timestamp":1374181277000},"page":"vi149-vi154","source":"Crossref","is-referenced-by-count":122,"special_numbering":"S6","title":["Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"24","author":[{"given":"R.","family":"Willemze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt242_bb0010","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO\u2013EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0015","series-title":"WHO Classification of Tumours Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdt242_bb0020","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2133.2003.05476.x","article-title":"Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems","volume":"149","author":"Tan","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdt242_bb0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jaad.2012.02.033","article-title":"World Health Organization\u2013European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution","volume":"67","author":"Park","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdt242_bb0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2008.07159.x","article-title":"Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma","volume":"142","author":"Senff","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt242_bb0045","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0050","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Eng J Med"},{"key":"10.1093\/annonc\/mdt242_bb0055","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdt242_bb0060","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt242_bb0065","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10670.x","article-title":"Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study","volume":"166","author":"Kamstrup","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdt242_bb0075","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt242_bb0080","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0085","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0090","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0095","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdt242_bb0105","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdt242_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2133.2000.03286.x","article-title":"Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies","volume":"142","author":"Russell-Jones","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdt242_bb0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdt242_bb0120","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0125","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0130","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.ijrobp.2007.08.077","article-title":"Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy","volume":"70","author":"Yu","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdt242_bb0135","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0140","article-title":"Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression","volume":"120","author":"Krathen","year":"2012","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mdt242_bb0145","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC Cutaneous Lymphoma Group study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt242_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":"Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdt242_bb0155","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdh268","article-title":"CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature","volume":"15","author":"Bekkenk","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0160","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt242_bb0165","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_6\/vi149\/6675093\/mdt242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T03:30:02Z","timestamp":1582169402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419315546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":32,"alternative-id":["S0923753419315546"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt242","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}